Last reviewed · How we verify
Temodal® or Dacarbazine Medac®
Temodal® or Dacarbazine Medac® is a Small molecule drug developed by SentoClone AB. It is currently in Phase 2 development. Also known as: DTIC, Dacarbazine, Temozolomide.
At a glance
| Generic name | Temodal® or Dacarbazine Medac® |
|---|---|
| Also known as | DTIC, Dacarbazine, Temozolomide |
| Sponsor | SentoClone AB |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Temodal® or Dacarbazine Medac® CI brief — competitive landscape report
- Temodal® or Dacarbazine Medac® updates RSS · CI watch RSS
- SentoClone AB portfolio CI
Frequently asked questions about Temodal® or Dacarbazine Medac®
What is Temodal® or Dacarbazine Medac®?
Temodal® or Dacarbazine Medac® is a Small molecule drug developed by SentoClone AB.
Who makes Temodal® or Dacarbazine Medac®?
Temodal® or Dacarbazine Medac® is developed by SentoClone AB (see full SentoClone AB pipeline at /company/sentoclone-ab).
Is Temodal® or Dacarbazine Medac® also known as anything else?
Temodal® or Dacarbazine Medac® is also known as DTIC, Dacarbazine, Temozolomide.
What development phase is Temodal® or Dacarbazine Medac® in?
Temodal® or Dacarbazine Medac® is in Phase 2.
Related
- Manufacturer: SentoClone AB — full pipeline
- Also known as: DTIC, Dacarbazine, Temozolomide
- Compare: Temodal® or Dacarbazine Medac® vs similar drugs
- Pricing: Temodal® or Dacarbazine Medac® cost, discount & access